Why This Matters to Distributors: The challenge centers on whether other suppliers can replace the competition between two national wholesalers with extensive delivery networks, broad product offerings, and rebate programs. It also highlights the role of online purchasing platforms in helping customers compare prices and negotiate with distributors.
The Federal Trade Commission and 13 states are suing to block Covetrus’ proposed $3.5 billion combination with MWI Animal Health, alleging the transaction would reduce competition, raise veterinary clinics’ costs, and weaken service.
The lawsuit, filed in the U.S. District Court for the Southern District of New York, seeks a permanent injunction preventing the deal. Covetrus disputes the government’s assessment and says veterinary practices have numerous purchasing alternatives.
Covetrus, based in Portland, Maine, distributes animal health products and provides pharmacy services, prescription management, and software for veterinary practices. It serves veterinarians caring for pets, horses, and livestock. The privately held company is owned by investment firms Clayton, Dubilier & Rice, and TPG.
When the merger was announced in February, Covetrus reported more than 5,000 employees and more than 100,000 customers worldwide. It did not disclose current annual revenue in that announcement or its response to the FTC.
MWI Animal Health, whose corporate office is in Boise, Idaho, distributes products and provides services to veterinarians, livestock producers, and agricultural retailers. Its business serves both companion animals and animals raised for food production.
MWI belongs to Cencora, the global pharmaceutical distributor. Cencora reported $5.69 billion in animal health revenue for fiscal 2025, up 6.1% from $5.37 billion a year earlier. For the nine months ended June 30, 2026, animal health revenue increased 5% to $4.43 billion from $4.21 billion. These figures cover Cencora’s global animal health business, rather than only the U.S. markets at issue in the lawsuit.
Cencora, based in Conshohocken, Pennsylvania, distributes pharmaceuticals and provides related services to pharmacies, health systems, physician practices, and other healthcare customers. It reported fiscal 2026 revenue of $337.4 billion, up 5%. The company said the MWI transaction would allow it to invest in other growth priorities while retaining an interest in the combined animal health business.
The FTC alleges that the deal would combine the two largest suppliers in veterinary clinic distribution and distribution to large corporate accounts. Their customers range from independent practices to veterinary groups operating hundreds of clinics.
The companies supply pharmaceuticals, vaccines, surgical products, gloves, gauze, syringes, and other supplies. According to the agency, their national distribution networks support rapid delivery and discounts and rebates that smaller competitors cannot match.
“This transaction will reduce competition in an already concentrated market and drive up prices for veterinarians and their customers,” said Daniel Guarnera, director of the FTC’s Bureau of Competition.
Regulators point to pricing competition between Covetrus and MWI as evidence of what customers could lose. According to Minnesota Attorney General Keith Ellison’s office, the complaint alleges that Covetrus responded to MWI’s aggressive pricing by lowering its prices and offering rebates through its VetSuite program.
Regulators say Vetcove, an online purchasing platform, intensified that competition by helping veterinary practices compare offers and use one distributor’s prices to negotiate with another. They contend that the merger would eliminate an important source of competitive pressure.
Covetrus argues that the government’s assessment overlooks how veterinary practices purchase supplies. In its Nov. 13 response, the company said clinics routinely buy the same products from multiple suppliers, negotiate directly with manufacturers, and place several orders each week.
The company said more than 60% of U.S. veterinary practices use online veterinary marketplaces, which provide access to more than 40 distributors and thousands of manufacturers. Those figures are company claims.
Covetrus also cited competition from manufacturers selling directly to clinics and retailers selling pharmaceuticals, treatments, and pet food directly to consumers. It said the merger would improve access to products and technology, maintain supply chain reliability, and lower the cost of serving practices.
The two sides offer different interpretations of online purchasing. Regulators describe price-comparison platforms as strengthening competition between Covetrus and MWI. Covetrus argues those platforms demonstrate that customers can shift purchases among a broader group of suppliers.
Regulators also allege that structural barriers would make it difficult for new competitors to replace the competition lost through the merger. Other suppliers provide some relevant products and services but do not sufficiently constrain veterinary clinic distributors, according to the states’ description of the complaint. Those allegations remain contested.
The companies announced the proposed combination Feb. 18. The agreement values MWI at $3.5 billion and would give Cencora $1.25 billion in cash, $800 million in preferred equity and a noncontrolling 34.3% common ownership stake valued at $1.45 billion.
The companies said the transaction would connect MWI’s distribution and supply chain capabilities with Covetrus’ technology, pharmacy, and practice management services. Completion remains subject to regulatory approval and other closing conditions.
Do not miss any content from Distribution Strategy Group. Join our list.
Share this article:

